Pseudoephedrine Hydrochloride

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]；H315 (17.2%): Causes skin irritation [Warning Skin corrosion/irritation]；H317 (73.9%): May cause an allergic skin reaction [Warning Sensitization, Skin]；H319 (17.2%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]；H335 (46%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]

P261, P264, P264+P265, P270, P271, P272, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 261 reports by companies from 24 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Status: Active Update: 17-06-2015 https://echa.europa.eu/registration-dossier/-/registered-dossier/12556

Pseudoephedrine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard

IMAP assessments - Benzenemethanol, .alpha.-[1-(methylamino)ethyl]-,hydrochloride, [S-(R*,R*)]-: Environment tier I assessment；IMAP assessments - Benzenemethanol, .alpha.-[1-(methylamino)ethyl]-,hydrochloride, [S-(R*,R*)]-: Human health tier I assessment

Pseudoephedrine acts directly on both alpha- and, to a lesser degree, beta-adrenergic receptors. Through direct action on alpha-adrenergic receptors in the mucosa of the respiratory tract, pseudoephedrine produces vasoconstriction. Pseudoephedrine relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors. Like ephedrine, pseudoephedrine releasing norepinephrine from its storage sites, an indirect effect. This is its main and direct mechanism of action. The displaced noradrenaline is released into the neuronal synapse where it is free to activate the postsynaptic adrenergic receptors.

Common adverse reactions include nervousness, restlessness, and insomnia. Rare adverse reactions include difficult/painful urination, dizziness/lightheadedness, heart palpitations, headache, increased sweating, nausea/vomiting, trembling, troubled breathing, unusual paleness, and weakness.

Drug Induced Liver Injury Rank (DILIrank 2.0)

Pseudoephedrine hydrochloride

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Status: Active Update: 17-06-2015 https://echa.europa.eu/registration-dossier/-/registered-dossier/12556

Pseudoephedrine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard

PSEUDOEPHEDRINE HCL

Adrenergic alpha-Agonists [MoA]; alpha-Adrenergic Agonist [EPC]

PSEUDOEPHEDRINE HYDROCHLORIDE

alpha-Adrenergic Agonist [EPC]; Adrenergic alpha-Agonists [MoA]

Agents, usually topical, that relieve itching (pruritus).

Agents that cause an increase in the expansion of a bronchus or bronchial tubes.

Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.

Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993)

Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)

For the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis. Also used as first-line therapy of priapism.